title: Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
abstract: OBJECTIVE
  Pegylated interferon (PEG-IFN) plus ribavirin (RBV) combination therapy is now a popular treatment for patients with chronic hepatitis C; however, the reported sustained virologic response (SVR) rate remains at nearly 50% in genotype 1b infected patients. Therefore, it is of clinical benefit to be able to predict the effect of combination therapy on individual patients earlier in the treatment. We estimated the predictive serum HCV core antigen levels for SVR in the early therapeutic stage of combination therapy.
  
  
  METHODS
  The HCV core antigen in patients with high-level HCV viremia, in whom standard PEG-IFNalpha2b plus RBV combination therapy had been completed, was measured at baseline and at 3, 7, 14, 28 and 84 days of treatment, and their SVR was determined at 24 weeks after treatment. Sixty genotype 1b- and 30 genotype 2-infected patients were included.
  
  
  RESULTS
  Thirty (50%) genotype 1b and 27 (90%) genotype 2 patients achieved a SVR. In genotype 1b patients the decline of HCV core antigen levels was statistically different between the SVR and non-SVR groups. When we defined a separation level at 500 fmol/L, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for SVR at day 7 was 79.4%, 88.5%, 90%, 76.7%, and 83.3%, respectively. In genotype 2 patients, there was no significant difference in the HCV core antigen values between the SVR and non-SVR groups.
  
  
  CONCLUSIONS
  In genotype 1b patients, 500 fmol/L of HCV core antigen level at day 7 was the best predictor for therapeutic response in the early stage of treatment.
authors.affiliation: Clinical Research Center, National Hospital Organization, Fukuoka, Japan.
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Fujino
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakamuta
authors.forename: Yoko
authors.initials: Y
authors.lastname: Aoyagi
authors.forename: Kunitaka
authors.initials: K
authors.lastname: Fukuizumi
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Takemoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Yoshimoto
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Miyahara
authors.forename: Naohiko
authors.initials: N
authors.lastname: Harada
authors.forename: Hironori
authors.initials: H
authors.lastname: Sakai
authors.forename: Manabu
authors.initials: M
authors.lastname: Nakashima
authors.forename: Munechika
authors.initials: M
authors.lastname: Enjoji
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D018936:Hepatitis C Antigens / Q000097:blood*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011237:Predictive Value of Tests; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D014758:Viral Core Proteins / Q000097:blood*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D015415:Biomarkers; D018936:Hepatitis C Antigens; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D014758:Viral Core Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b